内容紹介
Stevens-Johnson Syndrome Induced by Regorafenib in a Patient with Progressive Recurrent Rectal Carcinoma
Summary
A 55-year-old man with rectal carcinoma underwent lower anterior resection. Eight years after surgery, multiple metastases were detected in the liver, lung, and abdominal lymph nodes. The metastatic cancers were resistant to standard chemotherapy. Thus, regorafenib was administered to the patient. The patient presented symptoms of Stevens-Johnson syndrome(SJS)nine days after regorafenib administration, and hence, treatment was terminated. To treat SJS, he received oral and topical steroid therapies. SJS is an important adverse event that hinders the continuation of regorafenib treatment. Thus, it is necessary to continually check the patient's skin condition carefully, especially at early stages of treatment. To our knowledge, this is the first report of SJS arising during the course of regorafenib treatment.
要旨 症例は55歳,男性。直腸癌に対し低位前方切除術を施行された。術後8年で肝転移,肺転移,腹腔内リンパ節転移などを来し標準化学療法に抵抗性となり,regorafenibを導入した。導入後早期にStevens-Johnson症候群(SJS)を来し,投与中止の上,ステロイド内服・外用による治療を要した。SJSは治療継続困難となる重要な有害事象であり,導入早期に注意深く皮膚症状を観察することが必要である。本症例は,regorafenibによるSJSの初の報告例である。
目次
Summary
A 55-year-old man with rectal carcinoma underwent lower anterior resection. Eight years after surgery, multiple metastases were detected in the liver, lung, and abdominal lymph nodes. The metastatic cancers were resistant to standard chemotherapy. Thus, regorafenib was administered to the patient. The patient presented symptoms of Stevens-Johnson syndrome(SJS)nine days after regorafenib administration, and hence, treatment was terminated. To treat SJS, he received oral and topical steroid therapies. SJS is an important adverse event that hinders the continuation of regorafenib treatment. Thus, it is necessary to continually check the patient's skin condition carefully, especially at early stages of treatment. To our knowledge, this is the first report of SJS arising during the course of regorafenib treatment.
要旨 症例は55歳,男性。直腸癌に対し低位前方切除術を施行された。術後8年で肝転移,肺転移,腹腔内リンパ節転移などを来し標準化学療法に抵抗性となり,regorafenibを導入した。導入後早期にStevens-Johnson症候群(SJS)を来し,投与中止の上,ステロイド内服・外用による治療を要した。SJSは治療継続困難となる重要な有害事象であり,導入早期に注意深く皮膚症状を観察することが必要である。本症例は,regorafenibによるSJSの初の報告例である。